Didnt know this .. Its another timeline miss.. But
Post# of 148110
(Total Views: 617)
Posted On: 06/23/2020 11:28:10 AM
Didnt know this .. Its another timeline miss.. But will hopefully bring in some revenue with the discovery of all the CCR5 testing that could be needed with the spotlight of how important it is in many diseases.
Agreement represents a revenue opportunity as a diagnostic test for receptor occupancy and the existence of CCR5 on cancer tissue and in HIV
VANCOUVER, Washington, July 26, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the execution of an exclusive worldwide licensing agreement with IncellDX to sell non-commercial grade quantities of PA-14 or PRO 140 for use in the development and commercialization of immunoassays for quantitative measurement of CCR5 levels on human cells.
Under the terms of the agreement, IncellDX will be responsible, at its sole expense, for all aspects of assay development, regulatory clearance, including PA-14 or PRO140 labeling, packaging and commercialization. At the end of each month during the term of the agreement, IncellDX will provide to CytoDyn demand forecasts for PA-14 or PRO 140 for the subsequent 3-month period.
“The execution of the definitive agreement with IncellDX marks an important milestone for CytoDyn as it puts us firmly on pace to generate our first revenues over the course of the next several months,” stated CytoDyn President and CEO, Nader Pourhassan, Ph.D. “We are thankful to Dr. Patterson for recognizing the value of PA-14 and PRO 140 as a potent and valuable asset as a diagnostic test to measure CCR5 expression on human cells,” continued Dr. Pourhassan.
“IncellDX is very excited to license the exclusive worldwide diagnostic rights to CytoDyn’s CCR5 antibody that binds to the same site as PRO 140, an exciting therapeutic in trials for HIV and cancer,” stated Bruce Patterson, M.D., CEO and Founder of IncellDX. “This agreement fits with our strategy to develop companion diagnostics for powerful new classes of drugs,” continued Dr. Patterson. “We expect this new product line will be a major growth driver for IncellDX in the second half of 2019 and beyond,” concluded Dr. Patterson.
The Company also announced that its Board of Directors terminated the employment of Dr. Richard G. Pestell, the Company’s Chief Medical Officer, for cause pursuant to the terms of his employment agreement with the Company and pursuant to the terms of his employment agreement, upon such termination, Dr. Pestell resigned from his position as a director of the Company.
About Leronlimab (PRO 140)
The U.S. Food and Drug Administration (FDA) has granted a “Fast Track” designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer (mTNBC). Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases including NASH. Leronlimab has successfully completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients).
In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab can significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.
In the setting of cancer, research has shown that CCR5 plays an important role in tumor invasion and metastasis. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by >98% in a murine xenograft model. CytoDyn is therefore conducting a Phase 2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019. Additional research is being conducted with leronlimab in the setting of cancer and NASH with plans to conduct additional clinical studies when appropriate.
The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation and may be important in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to further support the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD and that blocking this receptor from recognizing certain immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted “orphan drug” designation to leronlimab for the prevention of graft-versus-host disease (GvHD).
Agreement represents a revenue opportunity as a diagnostic test for receptor occupancy and the existence of CCR5 on cancer tissue and in HIV
VANCOUVER, Washington, July 26, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the execution of an exclusive worldwide licensing agreement with IncellDX to sell non-commercial grade quantities of PA-14 or PRO 140 for use in the development and commercialization of immunoassays for quantitative measurement of CCR5 levels on human cells.
Under the terms of the agreement, IncellDX will be responsible, at its sole expense, for all aspects of assay development, regulatory clearance, including PA-14 or PRO140 labeling, packaging and commercialization. At the end of each month during the term of the agreement, IncellDX will provide to CytoDyn demand forecasts for PA-14 or PRO 140 for the subsequent 3-month period.
“The execution of the definitive agreement with IncellDX marks an important milestone for CytoDyn as it puts us firmly on pace to generate our first revenues over the course of the next several months,” stated CytoDyn President and CEO, Nader Pourhassan, Ph.D. “We are thankful to Dr. Patterson for recognizing the value of PA-14 and PRO 140 as a potent and valuable asset as a diagnostic test to measure CCR5 expression on human cells,” continued Dr. Pourhassan.
“IncellDX is very excited to license the exclusive worldwide diagnostic rights to CytoDyn’s CCR5 antibody that binds to the same site as PRO 140, an exciting therapeutic in trials for HIV and cancer,” stated Bruce Patterson, M.D., CEO and Founder of IncellDX. “This agreement fits with our strategy to develop companion diagnostics for powerful new classes of drugs,” continued Dr. Patterson. “We expect this new product line will be a major growth driver for IncellDX in the second half of 2019 and beyond,” concluded Dr. Patterson.
The Company also announced that its Board of Directors terminated the employment of Dr. Richard G. Pestell, the Company’s Chief Medical Officer, for cause pursuant to the terms of his employment agreement with the Company and pursuant to the terms of his employment agreement, upon such termination, Dr. Pestell resigned from his position as a director of the Company.
About Leronlimab (PRO 140)
The U.S. Food and Drug Administration (FDA) has granted a “Fast Track” designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer (mTNBC). Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases including NASH. Leronlimab has successfully completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients).
In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab can significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.
In the setting of cancer, research has shown that CCR5 plays an important role in tumor invasion and metastasis. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by >98% in a murine xenograft model. CytoDyn is therefore conducting a Phase 2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019. Additional research is being conducted with leronlimab in the setting of cancer and NASH with plans to conduct additional clinical studies when appropriate.
The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation and may be important in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to further support the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD and that blocking this receptor from recognizing certain immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted “orphan drug” designation to leronlimab for the prevention of graft-versus-host disease (GvHD).
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼